In the original research article entitled “Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection” by Andrzej Mackiewicz, Jacek Mackiewicz, Piotr J. Wysocki, Maciej Wiznerowicz, Malgorzata Kapcinska, Maria Laciak, Stefan Rose-John, Dariusz Izycki, Tomasz Burzykowski & Aldona Karczewska-Dzionk published in the June 2012 issue of Expert Opinion on Investigational Drugs (Expert Opin. Investig. Drugs (2012) 21(6): 773-783), the authors would like to correct an error in Figure 1.
In Figure 1 the upper-right hand panel legend, the DFS curve per stage at the beginning of the vaccination, the first key states IIIA/B. This should state IIIB as below:
The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.